| Source: | Federal Grant | |
| Clinical Trial Description: | Patients with HIV | |
| Principal Investigator: | Stephen T. Bartlett, M.D. | |
| Source: | Novartis | |
| Clinical Trial Description: | A 24-month, multi-center, randomized, open-label non-inferiority study of the efficacy and safety comparing two concentration-controlled Certican regimens with reduced Neoral versus Myfortic with standard dose Neoral in de novo renal transplant recipients | |
| Principal Investigator: | Matthew Cooper, M.D. | |
| Source: | Pfizer | |
| Clinical Trial Description: | A Phase 2 randomized , multicenter, active comparator-controlled trial to evaluate the safety and efficacy of coadministration of CP-690,550 and Mycophenolate Mofetil/Mycophenolate Sodium in de novo kidney allograft recipients (A3921030) | |
| Principal Investigator: | Matthew Cooper, M.D. | |
| Source: | Alavita | |
| Clinical Trial Description: | Phase 2, two-part study of the safety and tolerability of diannexin in kidney transplant recipients | |
| Principal Investigator: | Matthew Cooper, M.D. | |
| Source: | Astellas | |
| Clinical Trial Description: | A phase 2, randomized, open-label, parallel group, multi-center study to assess the safety and efficacy of alefacept in de novo kidney transplant recipients | |
| Principal Investigator: | Matthew Cooper, M.D. | |
| Source: | Wyeth | |
| Clinical Trial Description: | A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitor treatment to sirolimus treatment versus continued calcineurin inhibitor treatment in liver allograft recipients undergoing maintenance therapy | |
| Principal Investigator: | Luis Campos, M.D. | |
| Source: | Novartis | |
| Clinical Trial Description: | A 4-week multicenter, double-blind, randomized, parallel group study to compare the gastrointestinal safety and tolerability of myfortic and Cellcept when administered in combination with calcineurin inhibitors in renal transplant recipients experiencing gastrointestinal intolerance | |
| Principal Investigator: | Matthew Cooper, M.D. | |
| Source: | Novartis | |
| Clinical Trial Description: | A retrospective study comparing outcomes and costs associated with gastrointestinal side effects of myfortic v. Cellcept in renal transplant recipients | |
| Principal Investigator: | Matthew Cooper, M.D. | |
| Source: | Novartis | |
| Clinical Trial Description: | A facilitated access program to provide everolimus for maintenance patients completing therapy in RAD trials in solid organ transplantation | |
| Principal Investigator: | Matthew Cooper, M.D. | |
| Source: | Novartis | |
| Clinical Trial Description: | "Predictors of Allograft Outcomes Relating to Optimal Induction and Immunosuppressive Regimens for Populations at High Immunological Risk for Poorer Allograft Outcomes" | |
| Principal Investigator: | Benjamin Philosophe, M.D., Ph.D. | |
| Clinical Trial Description: | A screening protocol and research registry for the clinical research unit at the University of Maryland Division of Transplantation | |
| Principal Investigator: | Matthew Cooper, M.D. | |
Email this Page
Print this Page © 2009 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System, 22 S. Greene
Street, Baltimore, MD 21201. 1.800.492.5538 TDD: 1.800.735.2258
Physician Referral: 1.800.373.4111
Print this page
Email this page
Twitter
Facebook
YouTube
iPhone
